The global single-use bioreactors market is witnessing rapid growth, driven by the increasing demand for flexible and scalable bioprocessing solutions across biopharmaceutical and contract manufacturing sectors. Single-use bioreactors (SUBs) are replacing traditional stainless-steel systems due to their efficiency in reducing contamination risk, minimizing cleaning validation, and enabling faster product changeovers. These systems have become critical enablers for biologics, vaccines, and advanced therapies, including cell and gene therapies, as manufacturers aim to optimize production timelines and reduce operational costs. The COVID-19 pandemic further highlighted the advantages of disposable bioreactors in enabling rapid scale-up for vaccine and therapeutic manufacturing, reinforcing their strategic importance in modern bioprocessing.
Market statistics underscore the immense growth potential of this sector. The global single-use bioreactors market is projected to grow from US$ 4.2 billion in 2026 to US$ 8.5 billion by 2033, reflecting a CAGR of 10.4% during this period. Stirred-tank SUBs dominate the market by type, accounting for over 55-60% share, while single-use bioreactor systems hold approximately 43% of the product segment, reflecting their critical role in upstream cell culture processes. Geographically, North America leads the market, driven by a dense concentration of biopharma R&D centers, advanced therapy developers, and strong regulatory frameworks from agencies like the FDA. Meanwhile, the Asia Pacific region is emerging as the fastest-growing market due to large-scale investments in vaccine and biologics manufacturing in countries such as China, India, South Korea, and Japan, coupled with the rapid expansion of CDMOs offering multi-client production capabilities.
Download Your Free Sample & Explore Key Insights: https://www.persistencemarketresearch.com/samples/33957
Key Highlights from the Report
• The single-use bioreactors market is projected to reach US$ 8.5 billion by 2033, growing at a CAGR of 10.4%.
• North America holds the largest market share, driven by established biologics R&D and regulatory support.
• Asia Pacific is the fastest-growing region, fueled by large-scale biologics and vaccine investments.
• Single-use bioreactor systems dominate the product segment, accounting for around 43% share.
• Stirred-tank single-use bioreactors are the leading type due to process familiarity and scalability.
• Strong demand in cell and gene therapy manufacturing presents significant market growth opportunities.
Market Segmentation
The single-use bioreactors market can be segmented based on product type, bioreactor type, and end-user.
Product Type: Single-use bioreactor systems dominate the market due to their central role in upstream processing. These systems, including stirred-tank and wave-induced motion designs, offer rapid changeover, flexible volume ranges, and seamless integration with disposable media and filtration units. Their widespread adoption is supported by improvements in sensor integration, automation, and film technology, which enhance oxygen transfer, mixing, and overall process robustness. Other product categories, such as modular bioprocessing units and integrated disposable assemblies, are gaining traction in specialized applications, particularly in small-batch and clinical-scale production.
Bioreactor Type: Stirred-tank SUBs are the most commonly used configuration, offering well-characterized scale-up, efficient mixing, and compatibility with diverse cell lines, including mammalian, microbial, and insect systems. Wave-induced motion bioreactors are also employed, particularly for sensitive or shear-sensitive cell cultures, providing gentle agitation and improved cell viability. Each type of bioreactor serves distinct process requirements, enabling manufacturers to select systems based on product complexity, batch size, and scale-up needs.
End-User: Biopharma and pharmaceutical companies are the largest adopters, accounting for approximately 60% of demand. These organizations leverage single-use bioreactors to accelerate clinical development, optimize multiproduct pipelines, and reduce capital expenditures. Contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) also represent key end-users, using disposable systems to offer flexible, client-focused manufacturing services without the burden of extensive cleaning validation or high fixed capital costs.
Regional Insights
North America leads the global single-use bioreactors market, driven by a dense ecosystem of biopharma R&D centers, CDMOs, and biologics manufacturers. Strong regulatory frameworks from the FDA emphasize contamination control, closed processing systems, and robust process validation, encouraging the adoption of disposable bioreactors. Government initiatives promoting domestic vaccine and therapeutic manufacturing infrastructure further reinforce regional growth.
Europe represents a mature market with widespread adoption of single-use technologies in clinical and select commercial facilities. Key clusters in Germany, the U.K., France, and Spain focus on biologics, biosimilars, and antibody production. EMA regulations and European sustainability initiatives supporting reduced water and energy usage further drive single-use deployment.
Asia Pacific is the fastest-growing region, fueled by rapid expansion in biologics and vaccine manufacturing in China, India, South Korea, and Japan. Local and global CDMOs increasingly rely on disposable systems to achieve flexible, multi-client production. The region’s growth is supported by national programs for biologics self-reliance, favorable cost structures, and investment in workforce and supply chain development, positioning it as a global hub for single-use bioprocessing.
Get Custom Insights Designed for Your Business: https://www.persistencemarketresearch.com/request-customization/33957
Market Drivers
Several factors are propelling the growth of the single-use bioreactors market. The rapid expansion of biologics, vaccines, and advanced therapies, including cell and gene therapies, has created a critical need for flexible and modular bioprocessing systems. Single-use bioreactors enable faster facility deployment, reduce downtime associated with cleaning validation, and allow seamless product changeovers. The COVID-19 pandemic further highlighted the advantages of disposable systems in enabling rapid vaccine production and scale-up. Additionally, operational efficiency, reduced cross-contamination risk, and sustainability benefits, such as 20-30% lower water and energy consumption compared to traditional stainless-steel systems, make single-use bioreactors an attractive choice for manufacturers aiming to optimize resources while adhering to strict regulatory standards.
Market Restraints
Despite strong growth, certain challenges limit the broader adoption of single-use bioreactors. Concerns around extractables and leachables (E&L) from polymer-based components remain significant, requiring extensive regulatory testing and process validation. Material compatibility issues with specific media formulations or solvents can restrict their use in certain applications, especially for sensitive biologics or novel therapies. Mechanical reliability, including risks of bag tears, leaks, or failures in large-volume bioreactors, continues to pose operational risk. Additionally, environmental concerns related to polymeric waste disposal are prompting manufacturers to balance efficiency gains with sustainable practices, limiting rapid adoption in environmentally conscious markets.
Market Opportunities
The expanding cell and gene therapy sector represents one of the most compelling growth opportunities for single-use bioreactors. These therapies involve high-value, small-batch production that requires flexible, closed, and contamination-resistant manufacturing systems. Single-use bioreactors are particularly suited for upstream cell culture, viral vector production, and downstream processing in autologous and allogeneic therapies. The global pipeline of advanced therapies, with over 1,500 active clinical programs, continues to drive demand for modular, quickly deployable bioprocessing platforms, creating significant opportunities for suppliers offering pre-validated, functionally closed disposable systems.
Checkout Now & Download Complete Market Report: https://www.persistencemarketresearch.com/checkout/33957
Company Insights
Key players operating in the single-use bioreactors market include:
• Applikon Biotechnology BV – Specialized in small-scale and pilot bioreactors.
• Cellexus Ltd. – Offers wave-induced motion bioreactor systems.
• Celltainer Biotech B.V. – Focuses on integrated disposable bioprocessing solutions.
• Cesco Bioengineering Co. Ltd. – Supplies automated single-use bioreactors for research and production.
• Danaher Corporation – Parent company of Cytiva, providing comprehensive single-use solutions.
• ABEC, INC. – Designs disposable bioreactor vessels and modular systems.
• Distek, Inc. – Provides bioreactor automation and scale-up tools.
• Eppendorf SE – Manufactures benchtop and pilot-scale single-use systems.
• Thermo Fisher Scientific – Offers a wide portfolio, including the recently launched 5L DynaDrive Single-Use Bioreactor.
• Pall Corporation – Supplies filtration and integrated disposable assemblies.
• Sartorius AG – Provides modular single-use platforms for clinical and commercial production.
• Merck KGaA – Offers upstream and downstream single-use solutions.
• GE Healthcare – Supplies disposable bioreactors and process automation tools.
• Pierre Guerin – Focuses on modular cleanroom and single-use infrastructure.
Recent Developments:
In April 2025, Thermo Fisher Scientific launched the 5L DynaDrive Single-Use Bioreactor, designed for seamless scalability from 1 to 5,000 liters, accelerating bench-to-commercial transitions.
Sartorius AG expanded its single-use bioreactor portfolio with fully integrated modular systems supporting advanced therapy manufacturing, enhancing process automation and monitoring capabilities.
Conclusion
The single-use bioreactors market is poised for significant growth over the coming decade, driven by increasing demand for flexible, modular, and contamination-resistant bioprocessing solutions. Strong adoption in biologics, vaccines, and advanced therapies, combined with regulatory support and sustainability benefits, positions disposable systems as essential components of modern manufacturing. While challenges such as extractables, material compatibility, and environmental concerns persist, the rapid expansion of cell and gene therapy pipelines, particularly in Asia Pacific and North America, offers substantial growth opportunities. Leading market players continue to innovate in film technology, automation, and integrated platforms, ensuring that single-use bioreactors remain at the forefront of next-generation bioprocessing strategies.
